CEO Today USA Awards

CONNECTICUT www.ceotodaymagazine.com 42 CEO Today USAAwards 2017 of a new sales team selling the “one stop shop”, change of a cost center to a very successful profit center, and the societal benefit in providing a new cheaper better solution for early drug development. The financial story included a major turnaround from significant losses to profitability with over 20% annual revenue growth. Sales, revenue, contribution margin and operating margin increased by leveraging our capacity, increasing utilization and JONATHAN GOLDMAN CEO of Aptuit, an Evotec company Jonathan Goldman joined Aptuit as Chief Executive Officer in December of 2013. Prior to joining Aptuit, he held several executive positions at ICON Plc, a leading global contract research organization. His tenure at ICON included 3 years as global head of Business Development, as well as senior roles in operations and in medical imaging. He formerly served for 7 years as Chief Medical Officer of Point Biomedical, a development- stage biopharmaceutical company responsible for discovering and developing microsphere-based pharmaceuticals. He currently maintains a Faculty appointment as an Associate Clinical Professor of Medicine in the division of Cardiology at the University of California, San Francisco. Jonathan has also recently been awarded an Honorary Fellowship of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. Jonathan has BSc (1986), MBBS (1989) and MD (1995) degrees from the University of London, in addition to Executive MBA qualifications from Columbia University in New York, and the University of California at Berkeley. He trained in internal medicine and cardiology in leading UK and US institutions; his academic accomplishments include authorship of over 100 scientific publications and Fellowship of prominent medical societies, including the American College of Cardiology, the American Heart Association, and the Royal College of Physicians in the UK. Transformation of Aptuit under CEO tenure His role as CEO of Aptuit (www.aptuit.com) ran from Dec 2013 to Aug 2017 culminating in the sale to Evotec AG (www.evotec. com) for 300m$. This was a unique story and the most successful attempt to transform a former large pharma R and D center of excellence (a pure cost center) into a profitable and rapidly growing “one stop shop” for all drug discovery, development and manufacturing needs for pharmaceutical companies. The story involved amassive culture change, creation of a brand- new value proposition: the “Partner Research Organization” to increase success in drug discovery whilst reducing cost and timelines. In addition, in the process Aptuit significantly increased the workforce in 3 countries, became a preferred provider to many large and small companies whilst successfully discovering and developing a great number of new drugs completely in house for cancer, gastrointestinal disease, brain diseases (including Alzheimer’s and Parkinson’s), rare diseases and others. The success was based on innovation of a business model, launch ABOUT JONATHAN GOLDMAN